This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, Y. Articles by Terada, T. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, Y. Articles by Terada, T.

TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor and a Partial Agonist on Estrogen Receptor ß with Low Uterotrophic Effect

¹ Hanno Research Center, Taiho Pharmaceutical, Co. Ltd., Saitama, Japan, and² The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Yasuji Yamamoto, Hanno Research Center, Taiho Pharmaceutical Co. Ltd., 1-27 Misugidai, Hanno, Saitama 357-8527, Japan. Phone: 81-42-972-8900; Fax: 81-42-972-0034; E-mail: yas-yamamoto{at}taiho.co.jp.

Purpose: Investigators are currently conducting phase II trials on TAS-108, a novel oral steroidal antiestrogenic agent. The purpose of this study is to investigate the molecular and pharmacologic properties of TAS-108 comparedwith other antiestrogenic agents such as tamoxifen,raloxifene, and fulvestrant.

Experimental Design: The antagonistic or agonistic activities of these agents against both estrogen receptors (ER) and ß were compared in the reporter assay systems. Their effects on the uterus were evaluated in ovariectomized rat models. The antitumor activity of TAS-108 given p.o. was evaluated in both dimethylbenzanthracene-induced mammary tumor model and human breast cancer MCF-7 cell line xenografts.

Results: TAS-108 inhibited the transactivation of ER under the presence of 17ß-estradiol (E₂) and did not induce the transactivation of ER in the absence of E₂, unlike the agonistic activity of tamoxifen. On the other hand, it exhibited the most agonistic activity on ERß among the antiestrogenic agents tested. When given p.o. in the ovariectomized rat, TAS-108 showed a much weaker estrogenic effect on utterine weight compared to tamoxifen, or with similar levels of raloxifene, a selective estrogen receptor modulator. Also, TAS-108 strongly inhibited tumor growth in dimethylbenzanthracene-induced mammary carcinomain the rat, the endogenous E₂ model, at a dosage of 1 to 3 mg/kg/day. It also inhibited high exogenous E₂, inducing tumor growth against MCF-7 xenografts at a dosage of 1 mg/kg/day without any toxic manifestation.

Conclusions: Taken together, p.o. treatment with TAS-108 has a novel mode of action on ERs and inhibits E₂-dependent tumor growth with little uterotrophic effect.

Key Words: antiestrogen • breast cancer • estrogen receptor • SERM

This article has been cited by other articles:

				A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 689 - 706. [Abstract] [Full Text] [PDF]

				H. Yamaya, M. Saeki, K.-i. Yoshida, J. Shibata, S. Yano, Y. Sato, A. Takao, T. Shindo, A. U. Buzdar, and S. Nagayama DISTRIBUTION OF (7{alpha})-21-[4-[(DIETHYLAMINO) METHYL]-2-METHOXYPHENOXY]-7-METHYL-19-NORPREGNA-1,3,5(10)-TRIEN-3-OL-20-[14C]2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE ([14C]TAS-108) AND ITS METABOLITES AFTER SINGLE ORAL ADMINISTRATION TO RATS BEARING 7,12-DIMETHYLBENZ({alpha})ANTHRACENE-INDUCED MAMMARY TUMOR Drug Metab. Dispos., February 1, 2006; 34(2): 331 - 338. [Abstract] [Full Text] [PDF]